Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million

Published 05/22/2024, 12:10 PM
Updated 05/22/2024, 04:56 PM
© Reuters. FILE PHOTO: Bottles of Plavix are displayed on the shelves at a pharmacy in North Aurora, Illinois July 24, 2008.REUTERS/Jeff Haynes/File Photo
BMY
-
SNY
-

By Brendan Pierson

(Reuters) - A judge in Hawaii on Tuesday ordered Bristol Myers (NYSE:BMY) Squibb and Sanofi (NASDAQ:SNY) to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up from an earlier judgment of $834 million.

The ruling from Judge James Ashford (NYSE:AINC), of Hawaii's First Circuit Court, follows a non-jury trial held last fall. It was the second trial in the case, after the state's Supreme Court found that the judge in the first trial that resulted in the $834 million award had made a legal error.

"Once actually received by the state general fund, I anticipate that this award will provide greater healthcare services to the people of Hawaii," Governor Josh Green, a Democrat, said in a statement.

France-based Sanofi and U.S. drugmaker Bristol Myers said in a joint statement that they disagreed with the decision and would appeal. "The overwhelming body of scientific evidence demonstrates that Plavix is a safe and effective therapy, regardless of a patient’s race or genetics," they said.

Hawaii alleged the companies violated state consumer protection laws by marketing Plavix without disclosing that the drug could have a diminished or no effect for some people, particularly of East Asian and Pacific Island ancestry.

Plavix, known generically as clopidogrel, is prescribed to prevent blood clots that can lead to strokes and heart attacks. The blood thinner needs to be activated by the body's own enzymes, which can vary genetically.

Studies have shown that about 14% of Chinese patients are unable to metabolize the drug properly, compared with 4% of Black and 2% of white patients.

The U.S. Food and Drug Administration in 2010 issued a Plavix warning label to reflect that information.

© Reuters. FILE PHOTO: Bottles of Plavix are displayed on the shelves at a pharmacy in North Aurora, Illinois July 24, 2008.REUTERS/Jeff Haynes/File Photo

Bristol Myers and Sanofi faced a similar lawsuit from New Mexico, which settled in 2022.

(This story has been corrected to say New Mexico's lawsuit was settled in 2022, and is no longer pending, in paragraph 9)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.